Daily Cosmetic Research Analysis
Analyzed 20 papers and selected 3 impactful papers.
Summary
Three studies advance cosmetic science and dermatologic care: a PRISMA-compliant meta-analysis confirms ALA/MAL photodynamic therapy as an effective, cosmetically favorable option for basal cell carcinoma; single-cell microbiology shows EDTA suppresses a preservative-induced bacterial perseverance phenotype, informing preservation strategies; and a directed-screened Saccharomyces cerevisiae strain yields a yeast extract with enhanced UVA protection for skin cells.
Research Themes
- Cosmetically favorable cancer therapy (photodynamic therapy in BCC)
- Preservation science for cosmetic products (single-cell analysis of preservative responses)
- Bioengineered cosmetic ingredients for photoprotection (enhanced UVA-protective yeast extract)
Selected Articles
1. EDTA suppresses bacterial perseverance to 2-phenoxyethanol.
Using single-cell time-lapse microscopy in a microdevice, the authors demonstrate a perseverance phenotype under preservative exposure and show that EDTA suppresses bacterial perseverance to 2-phenoxyethanol. The work reframes preservation efficacy at the single-cell level and highlights EDTA as a functional booster candidate.
Impact: First demonstration of a perseverance-like phenotype in preservative-treated bacteria with a practical mitigation strategy is highly innovative and directly relevant to cosmetic product safety.
Clinical Implications: Better preservation strategies (e.g., EDTA as a booster) may reduce contamination risk in cosmetic and personal care products, potentially allowing lower preservative loads while maintaining safety.
Key Findings
- A perseverance phenotype occurs under preservative exposure, extending division in a subpopulation without genetic resistance.
- EDTA suppresses bacterial perseverance to the widely used preservative 2-phenoxyethanol.
- Single-cell time-lapse microscopy and microdevice assays reveal heterogeneous microbial behaviors relevant to preservation risk.
Methodological Strengths
- Single-cell time-lapse microscopy enabling direct observation of division dynamics under preservative stress
- Microdevice-based assay increasing environmental control and reproducibility
Limitations
- In vitro findings without quantitative population-level outcomes reported in the abstract
- Generalizability to complex cosmetic formulations and microbiomes remains to be established
Future Directions: Validate EDTA’s anti-perseverance effect across preservatives, species, and real formulations; define dosing windows that balance efficacy and material compatibility; and integrate single-cell readouts into preservation risk assessment frameworks.
Perseverance is a phenotype in which a small subpopulation of bacteria continues to divide for hours in the presence of antimicrobial concentrations that inhibit bulk population growth, without acquiring genetic resistance. Perseverance has previously been reported only in antibiotic-treated bacteria, but not in preservative-treated bacteria. However, perseverance could limit preservative efficacy, and we investigated this phenomenon in preservative-treated bacteria. Cosmetic products rely on preservatives to control microbial growth; however, preservative types and concentrations are limited for safety reasons, and boosters are often added to enhance efficacy. Some formulations also contain nutrients, such as plant extracts, that promote heterogeneous microbial behavior. Therefore, single-cell analyses are needed to understand these responses and assess preservation risk. In this study, we combined time-lapse microscopy and a microdevice to perform single-cell analysis of
2. Efficacy and safety of ALA/MLA photodynamic therapy for superficial and nodular basal cell carcinoma: a systematic review and meta-analysis.
Across 55 studies (2123 patients; 2995 lesions), ALA/MAL-PDT achieved high complete response and excellent/good cosmetic outcomes in both superficial and nodular BCC. MAL outperformed ALA in nodular BCC, while efficacy was comparable in superficial disease; emerging formulations (BF-200 ALA, AFL-MAL) showed promising results.
Impact: Provides comprehensive, quantitative evidence positioning PDT as a cosmetically favorable, non-invasive alternative to excision and clarifies ALA vs MAL choices by subtype.
Clinical Implications: Consider MAL-PDT for nodular BCC and either ALA or MAL-PDT for superficial BCC, especially in patients prioritizing cosmetic outcomes, multiple lesions, or surgical contraindications.
Key Findings
- Pooled complete response: 0.88 for superficial BCC; 0.75 for nodular BCC.
- Nodular BCC: MAL-PDT (0.78) significantly outperformed ALA-PDT (0.69), p=0.04; superficial BCC: no significant difference.
- Excellent/good cosmetic outcome rates were ~0.90 in both subtypes; adverse events were generally mild.
Methodological Strengths
- PRISMA 2020-adherent systematic review and meta-analysis across four major databases
- Subgroup analyses identifying key heterogeneity drivers (study design, light dose, session number)
Limitations
- High heterogeneity (I² up to 92%) and inclusion of single-arm studies
- Insufficient pooled adverse event data in nodular BCC and variable treatment parameters
Future Directions: Conduct head-to-head RCTs of MAL vs ALA in nodular BCC with standardized illumination protocols and long-term recurrence tracking; refine parameters for BF-200 ALA and AFL-MAL.
BACKGROUND: Basal cell carcinoma (BCC) is the most prevalent non-melanoma skin cancer, with surgical excision as the gold standard-though it carries risks of cosmetic scarring and functional impairment. Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) emerges as a non-invasive alternative, yet evidence on its relative efficacy across superficial (sBCC) and nodular (nBCC) subtypes remains inconsistent. METHODS: This systematic review and meta-analysis adhered to PRISMA 2020 guidelines, with a comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science up to December 31, 2025. Eligible studies included randomized controlled trials (RCTs) and single-arm studies evaluating ALA-PDT/MLA-PDT for histologically confirmed sBCC or nBCC. Study quality was assessed via the Methodological Index for Non-Randomized Studies (MINORS) scale, and statistical analyses were performed using Review Manager 5.4. RESULTS: A comprehensive literature search identified 3832 records, with 55 eligible studies (41 for sBCC, 34 for nBCC) ultimately included, involving 2123 patients and 2995 lesions. For sBCC, the pooled complete response (CR) rate was 0.88 (95% CI: 0.85-0.91, p<0.00001) with high heterogeneity (I²=87%); no significant difference in CR rate was observed between ALA-PDT (0.87) and MAL-PDT (0.90) (p=0.47), and BF-200 ALA-PDT achieved a CR rate of 0.90. The pooled beauty effect rate for sBCC was 0.91 (95% CI: 0.87-0.95, p<0.00001), with a low pooled adverse event incidence of 0.08 (95% CI: 0.03-0.14, p=0.004) and a pooled recurrence rate of 0.13 (95% CI: 0.09-0.18, p<0.00001). For nBCC, the pooled CR rate was 0.75 (95% CI: 0.70-0.80, p<0.00001, I²=92%), with MAL-PDT (0.78) showing a statistically significant higher CR rate than ALA-PDT (0.69) (p=0.04); BF-200 ALA-PDT and AFL-MAL-PDT achieved CR rates of 0.89 and 0.84, respectively. The pooled beauty effect rate for nBCC was 0.90 (95% CI: 0.83-0.96, p<0.00001), with a pooled recurrence rate of 0.15 (95% CI: 0.10-0.20, p<0.00001); adverse event data were insufficient for pooling, with individual studies reporting mild, manageable local reactions. Subgroup analyses revealed that study design, light dose, and number of treatment sessions were the main factors contributing to heterogeneity in key outcomes. CONCLUSIONS: ALA/MAL-PDT is an effective and safe non-invasive therapeutic option for both sBCC and nBCC, with excellent cosmetic outcomes for both subtypes. MAL-PDT exhibits significantly superior efficacy in nBCC compared with ALA-PDT, while the two photosensitizers show comparable therapeutic effects in sBCC. Novel PDT formulations including BF-200 ALA-PDT and AFL-MAL-PDT demonstrate promising CR rates for BCC, providing new treatment alternatives for clinical practice. Standardization of treatment parameters (e.g., light dose, treatment sessions) and differentiation of study design types can effectively reduce heterogeneity in PDT efficacy evaluation, and ALA/MAL-PDT should be prioritized for patients seeking minimally invasive treatment, those with multiple lesions, or those with contraindications to surgical excision.
3. A novel yeast extract from a multi-stress-resistant Saccharomyces cerevisiae confers potent antioxidant and UV-protective activities to skin cells.
A directed screening isolated a UVA-tolerant, multi-stress-resistant S. cerevisiae mutant (A154), whose yeast extract markedly enhanced UVA protection and ROS scavenging in human skin cell lines versus parental extract. At 0.5% extract, viability increased about 1.7-fold under UVA challenge.
Impact: Introduces a strain-selection strategy to engineer cosmetic bio-ingredients with enhanced photoprotection, bridging microbial stress biology and skin cell outcomes.
Clinical Implications: Supports development of next-generation UVA-protective cosmetic ingredients with antioxidant activity; requires safety, photostability, and clinical validation before use.
Key Findings
- Directed screening yielded a UVA-tolerant, multi-stress-resistant S. cerevisiae mutant (A154).
- A154 yeast extract showed significantly stronger UVA-protective and ROS-scavenging effects in human skin cell lines than parental extract.
- At 0.5% A154 extract, cell viability under UVA exposure increased approximately 1.7-fold (HFF, 120 kJ/m2 context indicated).
Methodological Strengths
- Directed evolution/screening approach linking microbial stress tolerance to functional skin cell outcomes
- Use of human skin cell lines to demonstrate UVA protection and antioxidant effects
Limitations
- In vitro cell-based data without in vivo or clinical validation
- Active molecular components of the extract and dose–response/toxicity profiles are not fully defined
Future Directions: Isolate/characterize active components, assess photostability and dermal penetration, and conduct in vivo safety and controlled clinical studies of UVA protection.
Yeast extract derived from Saccharomyces cerevisiae is a well-established cosmetic ingredient known for its diverse biological benefits, including UV protection. However, the directed optimization of yeast strains to obtain extracts with enhanced UVA protection for skin cells has not been previously reported. In this study, we developed a novel directed screening strategy to isolate a UVA-tolerant mutant strain, A154, which also exhibits multi-stress tolerance, including resistance to heat, oxidative stress, and UV radiation. Yeast extract from the A154 strain demonstrated significantly stronger UVA-protective and reactive oxygen species (ROS)-scavenging properties in human skin cell lines compared with the parental strain. In the presence of 0.5% A154 yeast extract, cell viability was increased by approximately 1.7-fold (HFF, 120 kJ/m